GU Cancers 2024 | What’s next for antibody drug conjugates in urothelial carcinoma?

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, comments on the future of antibody-drug conjugates (ADCs) for the management of urothelial carcinoma. Enfortumab vedotin has demonstrated very encouraging efficacy in clinical trials and the TROPiCS-04 trial (NCT04527991) will additionally investigate sacituzumab govitecan, a Trop2 directed ADC, in bladder cancer. Novel ADCs also include disitamab vedotin, which will be assessed against avelumab. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.